Now showing items 1-1 of 1

    • Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. 

      Sclafani, F; Kim, TY; Cunningham, D; Kim, TW; Tabernero, J; Schmoll, HJ; Roh, JK; Kim, SY; Park, YS; Guren, TK; Hawkes, E; Clarke, SJ; Ferry, D; Frodin, J-E; Ayers, M; Nebozhyn, M; Peckitt, C; Loboda, A; Watkins, DJ (2017-01)
      Limited data are available on the efficacy of anti-IGF-1R agents in KRAS mutant colorectal cancer (CRC). We analysed the outcome of 69 chemorefractory, KRAS exon 2 mutant CRC patients who were enrolled in a double-blind, ...